Lorcaserin - Epygenix Therapeutics/University of California at San Fransisco
Alternative Names: EPX 200Latest Information Update: 28 May 2024
At a glance
- Originator University of California at San Francisco
- Developer Epygenix Therapeutics; University of California at San Francisco; University of Colorado at Denver
- Class Antiepileptic drugs; Benzazepines; Obesity therapies; Small molecules
- Mechanism of Action 5-HT2C serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Lennox-Gastaut syndrome
- No development reported Dravet syndrome
Most Recent Events
- 28 May 2024 No recent reports of development identified for clinical-Phase-Unknown development in Dravet-syndrome in USA
- 30 Apr 2024 Epygenix Therapeutics has been acquired by Harmony Biosciences
- 07 Sep 2022 Loracaserin receives Rare Paediatric Disease Designation from US FDA for Lennox-Gastaut Syndrome prior to September 2022 (Epygenix Therapeutics pipeline, September 2022)